China Cerebral Infarction Treatment Market Size & Outlook
Related Markets
China cerebral infarction treatment market highlights
- The China cerebral infarction treatment market generated a revenue of USD 904.4 million in 2024 and is expected to reach USD 1,409.2 million by 2030.
- The China market is expected to grow at a CAGR of 7.7% from 2025 to 2030.
- In terms of segment, tissue plasminogen activators (tpa) was the largest revenue generating drug class in 2024.
- Anticoagulants is the most lucrative drug class segment registering the fastest growth during the forecast period.
Cerebral infarction treatment market data book summary
| Market revenue in 2024 | USD 904.4 million |
| Market revenue in 2030 | USD 1,409.2 million |
| Growth rate | 7.7% (CAGR from 2025 to 2030) |
| Largest segment | Tissue plasminogen activators (tpa) |
| Fastest growing segment | Anticoagulants |
| Historical data | 2018 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Tissue Plasminogen Activators (tPA), Anticoagulants, Antiplatelets, Anticonvulsants |
Other key industry trends
- In terms of revenue, China accounted for 6.7% of the global cerebral infarction treatment market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, China cerebral infarction treatment market is projected to lead the regional market in terms of revenue in 2030.
- South Korea is the fastest growing regional market in Asia Pacific and is projected to reach USD 312.9 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Cerebral Infarction Treatment Market Scope
Cerebral Infarction Treatment Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Amneal Pharmaceuticals Inc Ordinary Shares - Class A | View profile | 7700 | 400 Crossing Boulevard, 3rd Floor, Bridgewater, NJ, United States, 08807 | https://www.amneal.com |
| Daiichi Sankyo Co Ltd | View profile | 17435 | 3-5-1, Nihonbashi-honcho, Chuo-ku, Tokyo, Japan, 103-8426 | https://www.daiichisankyo.com |
| Bristol-Myers Squibb Co | View profile | 34100 | Route 206 and Province Line Road, Princeton, New Jersey, NJ, United States, 08543 | https://www.bms.com |
| Sanofi SA | View profile | 87994 | 46, avenue de la Grande Armée, Paris, France, 75017 | https://www.sanofi.com |
| Pfizer Inc | View profile | 88000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | https://www.pfizer.com |
| Otsuka Holdings Co Ltd | View profile | 39548 | 2-9 Kanda-Tsukasamachi, Chiyoda-ku, Tokyo, Japan, 101-0048 | http://www.otsuka.com/jp |
| Abbott Laboratories | View profile | 114000 | 100 Abbott Park Road, Abbott Park, IL, United States, 60064-6400 | https://www.abbottinvestor.com |
| Amgen Inc | View profile | 26700 | One Amgen Center Drive, Thousand Oaks, CA, United States, 91320-1799 | https://www.amgen.com |
| Novartis AG ADR | View profile | 76057 | Lichtstrasse 35, Basel, Switzerland, 4056 | https://www.novartis.com |
| Johnson & Johnson | View profile | 134400 | One Johnson and Johnson Plaza, New Brunswick, NJ, United States, 08933 | https://www.jnj.com |
China cerebral infarction treatment market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cerebral infarction treatment market will help companies and investors design strategic landscapes.
Tissue plasminogen activators (tpa) was the largest segment with a revenue share of 39.24% in 2024. Horizon Databook has segmented the China cerebral infarction treatment market based on tissue plasminogen activators (tpa), anticoagulants, antiplatelets, anticonvulsants covering the revenue growth of each sub-segment from 2018 to 2030.
The cerebral infarction treatment market in China is significantly influenced by the country’s large aging population, increasing incidence of stroke, and government-led healthcare reforms.
China accounts for nearly one-third of the global stroke burden, with approximately 2.5 million new stroke cases annually. The Chinese government has launched several initiatives, such as the National Stroke Screening Survey, aimed at early detection and prevention of stroke.
Additionally, investments in modernizing healthcare infrastructure, including developing stroke centers and adopting advanced treatment technologies, are driving growth in the Chinese market.
Reasons to subscribe to China cerebral infarction treatment market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of China cerebral infarction treatment market databook
-
Our clientele includes a mix of cerebral infarction treatment market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the China cerebral infarction treatment market , including forecasts for subscribers. This country databook contains high-level insights into China cerebral infarction treatment market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
China Drug Class - Cerebral Infarction Treatment Market size, 2024 - 2030 (US$M)
China Cerebral Infarction Treatment Market Outlook Share, 2024 & 2030 (US$M)
Related industry reports
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
